Search results
Pfizer (NYSE:PFE) Trading 0.3% Higher
ETF DAILY NEWS· 2 days agoPfizer Inc. (NYSE:PFE – Get Free Report) traded up 0.3% during mid-day trading on Tuesday . The company traded as high as $29.73 and last traded at $29.41. 9,834,266 shares ...
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Motley Fool via Yahoo Finance· 4 days agoPfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If...
FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
WUSF 89.7· 9 hours agoGovernment advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines...
2 Dividend Stocks Billionaires Are Buying: Should You? | The Motley Fool
The Motley Fool· 1 day agoMany billionaires are active on Wall Street and largely built their wealth that way. Of course,...
Pfizer didn’t sue Barbara O’Neill over bird flu secrets
Politifact· 5 days agoAn Instagram post from the same day claimed the recent legal troubles of hip-hop mogul Sean "Diddy"...
New COVID variant KP.3 climbs to 25%, now largest in CDC estimates
CBS News· 23 hours agoThe new KP.3 variant has climbed to 1 in 4 new COVID-19 cases nationwide, the Centers for Disease...
Pfizer Stock: Surging Cancer Rates Will Boost Revenues (NYSE:PFE)
Seeking Alpha· 1 day agoAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the...
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 16 hours agoTwo other companies – Pfizer and Moderna – also manufacture RSV vaccines approved for adults 60 and...
GSK RSV Vaccine Wins US Approval for Younger Age Group
Bloomberg· 18 hours agoHave a confidential tip for our reporters? GSK Plc’s vaccine for respiratory synctial virus was...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 1 day agoUsually, RSV causes coldlike symptoms in most people. But in newborns and older adults it can be...